Literature DB >> 1522541

Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor).

E Bailly1, R Jambou, J Savel, G Jaureguiberry.   

Abstract

We investigated the effect of a cysteine proteinase inhibitor (E-64) and an aspartyl proteinase inhibitor (Pepstatin A) on asexual erythrocytic stages of Plasmodium falciparum in culture. These two protease inhibitors showed different patterns of activity. E-64 acted preferentially against trophozoite and schizont stages. After 48 h incubation at high concentrations of E-64 (28, 140, 280 microM), growth was totally abolished and the parasites presented characteristic enlarged food vacuoles. Morphological alterations were also seen after shorter incubation periods (6 h at 28 microM) or 12 h at the inhibitory concentration 50% (12 microM), but an additional culture period (24 h) in inhibitor-free medium allowed normal parasite development, demonstrating a parasitostatic effect. E-64 acts on parasite multiplication; the normal merozoite maturation was altered and the normal reinvasion process partially impaired. Pepstatin A used at the inhibitory concentration 50% (4 microM) killed the parasites before trophozoite development and had a major effect on schizonts maturation. No altered parasite development occurred during an additional culture period without Pepstatin A, demonstrating a parasiticidal effect. E-64 and Pepstatin A used in combination inhibit the parasite growth with a strong synergistic effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1522541     DOI: 10.1111/j.1550-7408.1992.tb04856.x

Source DB:  PubMed          Journal:  J Protozool        ISSN: 0022-3921


  29 in total

1.  Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.

Authors:  T S Skinner-Adams; K T Andrews; L Melville; J McCarthy; D L Gardiner
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

2.  Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.

Authors:  Sunil Parikh; Jun Liu; Puran Sijwali; Jiri Gut; Daniel E Goldberg; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.

Authors:  Katherine T Andrews; David P Fairlie; Praveen K Madala; John Ray; David M Wyatt; Petrina M Hilton; Lewis A Melville; Lynette Beattie; Donald L Gardiner; Robert C Reid; Martin J Stoermer; Tina Skinner-Adams; Colin Berry; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Antimalarial synergy of cysteine and aspartic protease inhibitors.

Authors:  A Semenov; J E Olson; P J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 5.  Malaria parasite plasmepsins: More than just plain old degradative pepsins.

Authors:  Armiyaw S Nasamu; Alexander J Polino; Eva S Istvan; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2020-05-04       Impact factor: 5.157

6.  Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems.

Authors:  Jun Liu; Eva S Istvan; Ilya Y Gluzman; Julia Gross; Daniel E Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

7.  Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling.

Authors:  C S Gavigan; S G Machado; J P Dalton; A Bell
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum.

Authors:  Puran S Sijwali; Philip J Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

9.  Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.

Authors:  Subash Chandra Mohapatra; Hemandra Kumar Tiwari; Manisha Singla; Brijesh Rathi; Arun Sharma; Kuldeep Mahiya; Mukesh Kumar; Saket Sinha; Shyam Singh Chauhan
Journal:  J Biol Inorg Chem       Date:  2009-11-28       Impact factor: 3.358

10.  Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis.

Authors:  Peng Liu; Melissa R Marzahn; Arthur H Robbins; Hugo Gutiérrez-de-Terán; David Rodríguez; Scott H McClung; Stanley M Stevens; Charles A Yowell; John B Dame; Robert McKenna; Ben M Dunn
Journal:  Biochemistry       Date:  2009-05-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.